Evidence map›Paper›PMID 35889395›Full record

ArticleMolecules (Basel, Switzerland)2022

Critical Quality Control Methods for a Novel Anticoagulant Candidate LFG-Na by HPSEC-MALLS-RID and Bioactivity Assays.

Shunliang Zheng, Yi Wang, Jiashuo Wu, Siyao Wang, Huaifu Wei, Yongchun Zhang, Jianbo Zhou, Yue Shi

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Advances inFrontiers in nutrition · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shunliang ZhengInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.
Yi WangMudanjiang Youbo Pharmceutical Co., Ltd., Mudanjiang 157013, China.
Jiashuo WuInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.ORCID 0000-0003-1692-4729
Siyao WangMudanjiang Youbo Pharmceutical Co., Ltd., Mudanjiang 157013, China.
Huaifu WeiMudanjiang Youbo Pharmceutical Co., Ltd., Mudanjiang 157013, China.
Yongchun ZhangMudanjiang Youbo Pharmceutical Co., Ltd., Mudanjiang 157013, China.
Jianbo ZhouMudanjiang Youbo Pharmceutical Co., Ltd., Mudanjiang 157013, China.
Yue ShiInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.

Funding

Industry Incubation and Cluster Innovation Project of Marine Economic Innovation and Development Demonstration City of Haikou HHCF20180101NCHS CDC HHS R36 SH000004Special Funding for the Construction of Innovative Provinces in Hunan Province 2020SK2043the National Major Scientific and Technological Special Project for Significant New Drugs Development 2018ZX09711-001Transformation Project of Major Scientific and Technological Achievements of Heilongjiang Province ZC2018SH0004
6 · The paper itself

Abstract

A low molecular weight fucosylated glycosaminoglycan sodium (LFG-Na) is a novel anticoagulant candidate from the sea cucumber Holothuria fuscopunctata that selectively inhibits intrinsic tenase (iXase). The molecular weight, molecular weight distribution and bioactivities are the critical quality attributes of LFG-Na. The determination of these quality attributes of such an oligosaccharides mixture drug is challenging but critical for the quality control process to ensure its safety and efficacy in clinical use. Herein, the molecular weight and molecular weight distribution of LFG-Na were successfully determined using high performance size exclusion chromatography coupled with multi angle laser light scattering and refractive index detector (HPSEC-MALLS-RID). Comparing to the conventional method, HPSEC-MALLS-RID based on the refractive index increment (dn/dc) did not require the reference substances to establish the calibration curve. The acceptance criteria of LFG-Na were established, the weight-average molecular weight (Mw) should be 4000 to 6000 Da, the polydispersity (Mw/Mn) < 1.40, and the fraction with molecular weights of 1500 to 8000 Da should be no less than 80% of the total. HPSEC-MALLS-RID was also utilized for the determination of the starting material native fucosylated glycosaminoglycan (NFG) to choose a better manufacturing process. Furthermore, APTT assay was selected and the potency of anti-iXase, referring to the parallel line assay (PLA) method, was established to clarify the consistency of its biological activities. The results suggest that HPSEC-MALLS-RID and bioactivity assays are critical quality control methods for multi-component glycosaminoglycan LFG-Na. The methods also provide a feasible strategy to control the quality of other polysaccharide medicines.

Indexed as

AnticoagulantsGlycosaminoglycansAnimalsChromatography, GelMolecular WeightQuality ControlSodiumAnticoagulantsGlycosaminoglycansSodiumbioactivity assayHolothuria fuscopunctataHPSEC-MALLS-RIDLFG-Namolecular weightquality controlsea cucumber

Identifiers

PMID35889395
PMCPMC9318522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.